• Stephen Peary

Phizzle To Join StartEngine Community

I’m pleased to announce that Phizzle will be joining the StartEngine investment community.

As CFO of Phizzle, it’s important to chart a capital strategy that supports Phizzle’s market opportunity.

As we look to expand beyond our recent customer successes, we’ve determined the StartEngine community to be the most efficient path for Phizzle to gain access to growth capital.

As a company that prides itself on innovation, we believe at our core in taking different approaches to old problems and bringing novel ideas to existing markets. The democratization of capital markets through communities like StartEngine is exciting, and we’re pleased to be associated with it.


We also look forward to leading a new generation of B2B SaaS companies to enter the StartEngine portfolio. It’s important to expose a broader investing public to enterprise infrastructure opportunities.

Infrastructure software for enterprises may not be a household conversation, but it is a multi-trillion-dollar market. The segment of the enterprise market that Phizzle serves is unlikely to be a dinner topic! Afterall, how often does your family discuss scientific lab instruments like particle counters, pH meters or balances?

Our market exists because our F500 pharmaceutical customers rely on these sophisticated lab instruments to assure the FDA that drugs are safely produced for human and animal consumption. It’s been done this way for more than 50 years. We disrupt this traditional hardware-centric architecture with a modern, pharma-defined software architecture.

As a result, our software platform is the first and only in the industry to operate multiple types and brands of scientific instruments via a single user interface from a cloud. In consumer terms, we’re like a universal remote control operating in drug manufacturing laboratories. We make it easier, simpler and more accurate for our customers.

It’s a big breakthrough in productivity and cost-savings resulting from fewer human-caused data errors in pharmaceutical drug production. It’s why our software is already being used in real-world environments under recurring software licensing, maintenance and support contracts in F500 laboratories.


Click here to learn more about Phizzle on StartEngine.




 

Disclaimer

NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT IS FILED AND ONLY THROUGH AN INTERMEDIARY’S PLATFORM. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. "RESERVING" SECURITIES IS SIMPLY AN INDICATION OF INTEREST.

53 views0 comments